Discussing the Supreme Court’s decision in Mayo v. Prometheus to reject two patents on a method for monitoring a patient’s blood to determine appropriate drug dosage as well as the decision’s potential to affect the profitability of personalized medicine, Partner Courtenay Brinckerhoff said the rejection is a disruption of the status quo that may result in less funding for research. First published in an article that appeared in Reuters, Ms. Brinckerhoff’s comments later appeared in additional publications including the Chicago Tribune, Yahoo! News, BioPortfolio and The Huffington Post.
People
Related News
June 11, 2025
In the News
Foley Named Top US Firm for IP Lateral Hires by ManagingIP
Foley & Lardner LLP was named the top United States firm for intellectual property lateral partner hires in April and May 2025 based on data from ManagingIP's Talent Tracker.
June 10, 2025
In the News
Lynn Gandhi Sheds Light on Supreme Court Tax Ruling
Foley partner Lynn Gandhi commented in the Bloomberg Tax article "High Court’s Catholic Charities Case to Go Beyond Unemployment," sharing insight on the implications of a recent Supreme Court ruling in a tax case.
June 10, 2025
In the News
James McFall Joins Iconic Athletes and Leaders in Launch of Stanford Football Alumni United
Foley & Lardner LLP is proud to announce that partner James Carlos McFall is a founding member of Stanford Football Alumni United (SFAU), a newly formed coalition of former players and leaders committed to supporting Stanford Football’s continued growth and national competitiveness.